We found previously that Ki16425, which is a competitive inhibitor of LPA1 and LPA3 receptors (17), inhibits efficiently the progression of breast cancer cell-mediated bone metastases in a mouse model (16). This evidence concerns the gene LPAR1 and breast cancer.